Chemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysis

Gastroenterology

Volumn 122, Issue 1, 2002, Pages 78-84

  Suleiman, Saud ^a   Rex, Douglas K ^b   Sonnenberg, Amnon ^a  

^a VA Medical Center   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CANCER PREVENTION; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0036143855     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.29689     Document Type: Article

References (51)

1. Epidemiology of colorectal adenomas
2. Prevention of colorectal cancer by colonoscopic polypectomy
3. Protection by endoscopy against death from colorectal cancer: A case control study among veterans
4. The cost-effectiveness of colonoscopy in screening for colorectal cancer
5. Screening for colorectal cancer
6. Cost-effectiveness model for colorectal cancer screening
7. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne colorectal cancer study
8. Aspirin use and reduced risk of fatal colon cancer
9. Reduced risk of large bowel adenomas among aspirin users
10. Aspirin and non-steroidal anti-inflammatory agents and risk for colorectal adenomas
11. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
12. Aspirin and the risk of colorectal cancer in women
13. Aspirin use, cancer, and polyps of the large bowel
14. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
15. Cyclooxygenase, NSAIDs, and colorectal cancer
16. Effects of long-term sulindac therapy on colonic polyposis
17. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
18. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment
19. Nonsteroidal anti-inflammatory agents in chemoprevention of colorectal cancer. At what cost?
20. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis
21. Excess cost from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs
22. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen. Retrospective cohort study of an elderly population
23. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer
24. Polyps and cancer of the large bowel: A necropsy study in Liverpool
25. Prevention of colorectal cancer by flexible endoscopy: A case control study of 32,702 veterans
26. A case control study of screening sigmoidoscopy and mortality from colorectal cancer
27. Colorectal cancer screening: Clinical guidelines and rationale
28. Performing a cost-effectiveness analysis: Surveillance of patients with ulcerative colitis
29. The hospital costs for diagnosis and treatment of colorectal cancer
30. Foundations of cost-effectiveness for health and medical practices
31. Reporting cost-effectiveness studies and results
32. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
33. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
34. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
35. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
36. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
37. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
38. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis
39. Cost-effectiveness of stroke prevention
40. Cost-effectiveness of new antiplatelet regimes used as secondary prevention of stroke or transient ischemic attack
41. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
42. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
43. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
44. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease
45. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
46. Aspirin for primary prevention of cardiovascular events
47. Cost-effectiveness of primary and secondary prevention in cardiovascular disease